950'un PE Oranı emsallerine kıyasla nasıldır?

950 Price-To-Earnings Oranı ( 11.5 x) açısından benzer ortalamaya ( 7.9 x) kıyasla pahalıdır.

950'nin PE Oranı, HK Pharmaceuticals Sektöründeki diğer şirketlerle karşılaştırıldığında nasıldır?

950 Price-To-Earnings Oranı ( 11.5 x) baz alındığında, Hong Kong Pharmaceuticals sektör ortalamasına ( 8.4 x) kıyasla pahalıdır.

950'nin PE Oranı, Adil PE Oranına kıyasla nedir? Bu, şirketin tahmini kazanç büyümesini, kar marjlarını ve diğer risk faktörlerini dikkate alan beklenen PE Oranıdır.

Değerleme analizi için 950 'in Price-To-Earnings Adil Oranını hesaplamak için yeterli veri yok.

Gelecekteki nakit akışlarına bakıldığında 950 'un Adil Fiyatı nedir? Bu tahmin için İndirgenmiş Nakit Akışı modelini kullanıyoruz.

950 ( HK$1.23 ) [[adil değer]] tahminimizin üzerinde işlem görüyor ( HK$0.66 )

Analistin 12 aylık tahmini nedir ve konsensüs fiyat hedefine istatistiksel olarak güveniyor muyuz?

Fiyat tahminini göstermek için yeterli veri yok.

Lee's Pharmaceutical Holdings (SEHK:950) - Hisse Senedi Fiyatı, Haberler ve Analizler

950 Stoklara Genel Bakış

950 temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	4/6
Finansal Sağlık	5/6
Temettüler	1/6

Ödüller

Kazançlar geçen yıl 61.9% oranında arttı

Risk Analizi

Kazançlar son 5 yılda yılda 14.9% oranında azaldı

Anlamlı bir piyasa değeri yok ( HK$724M )

Lee's Pharmaceutical Holdings Limited Rakipler

Lansen Pharmaceutical Holdings

SEHK:503

HK$750.6m

Zhongzhi Pharmaceutical Holdings

SEHK:3737

HK$777.2m

Jilin Province Huinan Changlong Bio-pharmacy

SEHK:8049

HK$790.0m

Pak Fah Yeow International

SEHK:239

HK$760.4m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Lee's Pharmaceutical Holdings
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	HK$1.23
52 Haftanın En Yüksek Seviyesi	HK$1.75
52 Haftanın En Düşük Seviyesi	HK$1.00
Beta	0.87
11 Aylık Değişim	-2.38%
3 Aylık Değişim	0%
1 Yıllık Değişim	-7.52%
33 Yıllık Değişim	-64.66%
5 Yıllık Değişim	-69.70%
Halka arzdan bu yana değişim	136.54%

Son Haberler & Güncellemeler

Lee's Pharmaceutical Holdings' (HKG:950) Earnings Are Weaker Than They Seem

Sep 04

Recent updates

Lee's Pharmaceutical Holdings' (HKG:950) Earnings Are Weaker Than They Seem

Sep 04

There's Reason For Concern Over Lee's Pharmaceutical Holdings Limited's (HKG:950) Price

Aug 07

Lee's Pharmaceutical Holdings (HKG:950) Has Affirmed Its Dividend Of HK$0.01

May 21

Optimistic Investors Push Lee's Pharmaceutical Holdings Limited (HKG:950) Shares Up 28% But Growth Is Lacking

Dec 20

Can Mixed Fundamentals Have A Negative Impact on Lee's Pharmaceutical Holdings Limited (HKG:950) Current Share Price Momentum?

Mar 17

Should You Buy Lee's Pharmaceutical Holdings Limited (HKG:950) For Its 0.9% Dividend?

Feb 22

What Type Of Returns Would Lee's Pharmaceutical Holdings'(HKG:950) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Jan 29

What Type Of Shareholders Own The Most Number of Lee's Pharmaceutical Holdings Limited (HKG:950) Shares?

Jan 12

Hissedar Getirileri

	950	HK Pharmaceuticals	HK Pazar
7D	-3.9%	0.8%	0.4%
1Y	-7.5%	-7.5%	12.0%

Getiri vs. Endüstri: 950 geçen yıl boyunca % -7.5 oranında getiri sağlayan Hong Kong Pharmaceuticals sektörüyle eşleşti.

Getiri vs Piyasa: 950 geçen yıl % 12 oranında getiri sağlayan Hong Kong Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is 950's price volatile compared to industry and market?
950 volatility
950 Average Weekly Movement	6.9%
Pharmaceuticals Industry Average Movement	6.8%
Market Average Movement	8.9%
10% most volatile stocks in HK Market	18.9%
10% least volatile stocks in HK Market	4.3%

İstikrarlı Hisse Senedi Fiyatı: 950 son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: 950 'nin haftalık oynaklığı ( 7% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1994	993	n/a	www.leespharm.com

Bir yatırım holding şirketi olan Lee's Pharmaceutical Holdings Limited, öncelikle Çin Halk Cumhuriyeti'nde farmasötik ürünler geliştirmekte, üretmekte, pazarlamakta ve satmaktadır. Kardiyovasküler, kadın sağlığı, pediatri, nadir hastalıklar, onkoloji, dermatoloji ve obstetrik dahil olmak üzere çeşitli hastalık alanlarına odaklanmaktadır. Tescilli ve Jenerik Ürünler; ve Lisanslı Ürünler bölümleri aracılığıyla faaliyet göstermektedir.

Lee's Pharmaceutical Holdings Limited Temel Bilgiler Özeti

Lee's Pharmaceutical Holdings'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
950 temel i̇stati̇sti̇kler
Piyasa değeri	HK$724.27m
Kazançlar(TTM)	HK$63.06m
Gelir(TTM)	HK$1.20b

11.5x

F/K Oranı

0.6x

P/S Oranı

950 aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
950 gelir tablosu (TTM)
Gelir	HK$1.20b
Gelir Maliyeti	HK$581.63m
Brüt Kâr	HK$617.44m
Diğer Giderler	HK$554.38m
Kazançlar	HK$63.06m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	0.11
Brüt Marj	51.49%
Net Kâr Marjı	5.26%
Borç/Özkaynak Oranı	14.2%

950 uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Temettüler

2.4%

Mevcut Temettü Verimi

28%

Ödeme Oranı

950 Stoklara Genel Bakış

Ödüller

Risk Analizi

Lee's Pharmaceutical Holdings Limited Rakipler

SEHK:503

HK$750.6m

SEHK:3737

HK$777.2m

SEHK:8049

HK$790.0m

SEHK:239

HK$760.4m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Investor sentiment improves as stock rises 16%

Board Member recently bought HK$66k worth of stock

Lee's Pharmaceutical Holdings' (HKG:950) Earnings Are Weaker Than They Seem

First half 2024 earnings released: EPS: HK$0.11 (vs HK$0.027 in 1H 2023)

First half dividend of HK$0.02 announced

Lee's Pharmaceutical Holdings Limited to Report First Half, 2024 Results on Aug 28, 2024

Recent updates

Investor sentiment improves as stock rises 16%

Board Member recently bought HK$66k worth of stock

Lee's Pharmaceutical Holdings' (HKG:950) Earnings Are Weaker Than They Seem

First half 2024 earnings released: EPS: HK$0.11 (vs HK$0.027 in 1H 2023)

First half dividend of HK$0.02 announced

Lee's Pharmaceutical Holdings Limited to Report First Half, 2024 Results on Aug 28, 2024

There's Reason For Concern Over Lee's Pharmaceutical Holdings Limited's (HKG:950) Price

Lee's Pharmaceutical Holdings Limited Announces the First Patient Has Been Enrolled in A Phase I Clinical Trial to Receive Au409 At Queen Mary Hospital, Hong Kong

Board Member recently bought HK$59k worth of stock

Board Member recently bought HK$117k worth of stock

Lee's Pharmaceutical Holdings Limited Appoints Huang Zuie Chin as A Non-Executive Director

Board Member recently bought HK$120k worth of stock

Board Member recently bought HK$61k worth of stock

Lee's Pharmaceutical Holdings (HKG:950) Has Affirmed Its Dividend Of HK$0.01

Upcoming dividend of HK$0.01 per share

Board Member recently bought HK$130k worth of stock

Less than half of directors are independent

Final dividend of HK$0.01 announced

Lee's Pharmaceutical Holdings Limited, Annual General Meeting, May 22, 2024

Full year 2023 earnings released: EPS: HK$0.028 (vs HK$0.087 in FY 2022)

Lee's Pharmaceutical Holdings Limited Proposes Ordinary Final Dividend for the Year Ended 31 December 2023, Payable on 17 June 2024

Lee's Pharmaceutical Holdings Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

Board Member recently bought HK$123k worth of stock

New minor risk - Market cap size

Board Member recently bought HK$75k worth of stock

Investor sentiment improves as stock rises 15%

Optimistic Investors Push Lee's Pharmaceutical Holdings Limited (HKG:950) Shares Up 28% But Growth Is Lacking

Investor sentiment improves as stock rises 18%

Board Member recently bought HK$50k worth of stock

Board Member recently bought HK$113k worth of stock

Senior Adviser & Non-Executive Director recently bought HK$347k worth of stock

Investor sentiment improves as stock rises 17%

Senior Adviser & Non-Executive Director recently bought HK$110k worth of stock

Senior Adviser & Non-Executive Director recently bought HK$76k worth of stock

Investor sentiment improves as stock rises 18%

Price target decreased by 55% to HK$1.10

Lee's Pharmaceutical Holdings Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, Payable on 04 October 2023

First half 2023 earnings released: EPS: HK$0.027 (vs HK$0.048 in 1H 2022)

New minor risk - Market cap size

Lee's Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023

Lee's Pharmaceutical Holdings Limited to Report First Half, 2023 Results on Aug 30, 2023

Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01

Lee's Pharmaceutical Holdings Limited Appoints Cheang Yee Wah, Eva as Independent Non-Executive Director

Upcoming dividend of HK$0.01 per share at 1.3% yield

Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01

Full year 2022 earnings released: EPS: HK$0.087 (vs HK$3.38 in FY 2021)

Lee's Pharmaceutical Holdings Limited Announces Inclusion of Treprostinil Injection, Teglutik and Trittico in the National Reimbursement Drug List

Third quarter 2022 earnings released: EPS: HK$0.058 (vs HK$0.024 in 3Q 2021)

Price target decreased to HK$1.80

Less than half of directors are independent

Lee's Pharmaceutical Holdings Limited to Report Q3, 2022 Results on Nov 17, 2022

Lee's Pharmaceutical Holdings Limited Announces Completion of Patient Enrolment for A Phase III Clinical Trial of Intrarosa

Price target decreased to HK$1.80

Upcoming dividend of HK$0.01 per share

Lee's Pharmaceutical Holdings' (HKG:950) Dividend Is Being Reduced To HK$0.01

Lee's Pharmaceutical Holdings Limited Announces Interim Dividend for the Six Months Ended June 30, 2022, Payable on September 27, 2022

Second quarter 2022 earnings released: EPS: HK$0.014 (vs HK$3.59 in 2Q 2021)

Lee's Pharmaceutical Holdings Limited to Report First Half, 2022 Results on Aug 26, 2022

Lee's Pharmaceutical Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2022